DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, specializing in the development of novel epicutaneous immunotherapy products for the treatment of food allergies. Utilizing its proprietary Viaskin™ technology platform, DBV aims to provide non-invasive treatment solutions that facilitate allergen desensitization, significantly improving patient quality of life. The company’s robust pipeline, which includes lead candidates specifically targeting peanut allergies along with several ongoing clinical trials, underscores its potential to revolutionize the allergy treatment landscape and address a pressing unmet medical need.
Click "Analyze" to generate stock analysis
DBVT Price Trend and Signals
DBVT Financials
2025-10-23Somewhat Bearishmacd_signal
Dead cross above zero detected.
2025-10-16Somewhat Bullishprice_signal
Yearly high detected.
2025-10-15Neutralvolume_signal
Abnormal volume detected compared to 20-day moving average.
2025-10-15Neutralvolume_signal
Abnormal volume detected compared to 3 mon moving average.